Birchview Capital
Latest statistics and disclosures from Birchview Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BMY, BDSX, NBIX, PRTA, AZYO, and represent 62.25% of Birchview Capital's stock portfolio.
- Added to shares of these 8 stocks: BDSX (+$6.1M), ATEC, HALO, PRTA, AZYO, TXG, KROS, KPTI.
- Started 3 new stock positions in TXG, KROS, HALO.
- Reduced shares in these 10 stocks: Continental Resources, , VTYX, NARI, AVEO, IRTC, GOSS, FOLD, NBIX, Biohaven Pharmaceutical Holding.
- Sold out of its positions in Chemocentryx, Continental Resources, Contrafect, IRTC, NARI, LSF.
- Birchview Capital was a net buyer of stock by $2.6M.
- Birchview Capital has $142M in assets under management (AUM), dropping by -0.31%.
- Central Index Key (CIK): 0001618205
Tip: Access up to 7 years of quarterly data
Positions held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv

Portfolio Holdings for Birchview Capital
Birchview Capital holds 57 positions in its portfolio as reported in the December 2022 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Bristol Myers Squibb (BMY) | 37.0 | $52M | 728k | 71.95 | ||
Biodesix (BDSX) | 8.2 | $12M | +112% | 5.0M | 2.30 | |
Neurocrine Biosciences (NBIX) | 7.1 | $10M | 84k | 119.44 | ||
Prothena Corp SHS (PRTA) | 5.4 | $7.7M | +6% | 127k | 60.25 | |
Aziyo Biologics (AZYO) | 4.5 | $6.4M | +6% | 1.5M | 4.25 | |
Quidel Corporation | 3.7 | $5.3M | 61k | 85.67 | ||
Encana Corporation (OVV) | 3.0 | $4.3M | 84k | 50.71 | ||
United Therapeutics Corporation (UTHR) | 2.9 | $4.2M | 15k | 278.07 | ||
ACADIA Pharmaceuticals (ACAD) | 2.8 | $4.0M | 249k | 15.92 | ||
Phreesia (PHR) | 1.9 | $2.7M | 83k | 32.36 | ||
Harrow Health (HROW) | 1.9 | $2.7M | 180k | 14.76 | ||
Albireo Pharma (ALBO) | 1.8 | $2.5M | 117k | 21.61 | ||
Masimo Corporation (MASI) | 1.6 | $2.3M | 15k | 147.97 | ||
Inhibrx (INBX) | 1.2 | $1.7M | 70k | 24.64 | ||
Setup an alertBirchview Capital will file the next quarterly 13-HR in about 2 months. Would you like to be notified? |
||||||
Foghorn Therapeutics (FHTX) | 1.2 | $1.7M | 265k | 6.38 | ||
Accelr8 Technology (AXDX) | 1.1 | $1.6M | 2.3M | 0.71 | ||
Aveo Pharmaceuticals (AVEO) | 1.1 | $1.5M | -28% | 100k | 14.95 | |
Alkermes SHS (ALKS) | 0.9 | $1.3M | 50k | 26.14 | ||
Cytokinetics (CYTK) | 0.8 | $1.1M | 25k | 45.84 | ||
Alphatec Holdings (ATEC) | 0.8 | $1.1M | +800% | 90k | 12.36 | |
Corcept Therapeutics Incorporated (CORT) | 0.7 | $1.0M | 50k | 20.32 | ||
Karyopharm Therapeutics (KPTI) | 0.7 | $991k | +8% | 291k | 3.40 | |
Equitrans Midstream Corp (ETRN) | 0.6 | $891k | 133k | 6.70 | ||
Pioneer Natural Resources (PXD) | 0.6 | $868k | 3.8k | 228.42 | ||
Docgo (DCGO) | 0.5 | $778k | 110k | 7.07 | ||
ImmunoGen (IMGN) | 0.5 | $744k | 150k | 4.96 | ||
Ventyx Biosciences (VTYX) | 0.5 | $721k | -51% | 22k | 32.77 | |
Bluebird Bio (BLUE) | 0.5 | $678k | 98k | 6.92 | ||
Apellis Pharmaceuticals (APLS) | 0.4 | $621k | 12k | 51.75 | ||
Halozyme Therapeutics (HALO) | 0.4 | $569k | NEW | 10k | 56.90 | |
2seventy Bio (TSVT) | 0.4 | $561k | 60k | 9.38 | ||
Iveric Bio (ISEE) | 0.4 | $535k | 25k | 21.40 | ||
Silk Road Medical Inc Common (SILK) | 0.4 | $529k | 10k | 52.90 | ||
Arvinas Ord (ARVN) | 0.4 | $513k | 15k | 34.20 | ||
Soleno Therapeutics | 0.3 | $485k | 245k | 1.98 | ||
Kiniksa Pharmaceuticals (KNSA) | 0.3 | $449k | 30k | 14.97 | ||
Protagonist Therapeutics (PTGX) | 0.3 | $415k | 38k | 10.92 | ||
Xenon Pharmaceuticals (XENE) | 0.3 | $394k | 10k | 39.40 | ||
10x Genomics Cl A Com (TXG) | 0.3 | $364k | NEW | 10k | 36.40 | |
Amicus Therapeutics (FOLD) | 0.2 | $342k | -26% | 28k | 12.21 | |
Keros Therapeutics (KROS) | 0.2 | $336k | NEW | 7.0k | 48.00 | |
Sarepta Therapeutics (SRPT) | 0.2 | $324k | 2.5k | 129.60 | ||
Xencor (XNCR) | 0.2 | $320k | 12k | 26.02 | ||
Kalvista Pharmaceuticals (KALV) | 0.2 | $270k | 40k | 6.75 | ||
Nektar Therapeutics (NKTR) | 0.2 | $267k | -7% | 118k | 2.26 | |
Cullinan Oncology (CGEM) | 0.2 | $265k | 25k | 10.55 | ||
BioCryst Pharmaceuticals (BCRX) | 0.2 | $230k | 20k | 11.50 | ||
G1 Therapeutics (GTHX) | 0.2 | $217k | 40k | 5.42 | ||
Inflarx Nv (IFRX) | 0.2 | $217k | 70k | 3.10 | ||
Gossamer Bio (GOSS) | 0.2 | $215k | -37% | 99k | 2.17 | |
Stoke Therapeutics (STOK) | 0.1 | $138k | 15k | 9.20 | ||
Concert Pharmaceuticals I equity (CNCE) | 0.1 | $117k | 20k | 5.85 | ||
Biohaven Pharmaceutical Holding | 0.1 | $102k | -50% | 7.4k | 13.85 | |
Angion Biomedica Corp (ANGN) | 0.0 | $44k | 54k | 0.81 | ||
Yield10 Bioscience | 0.0 | $31k | 19k | 1.65 | ||
Aspira Womens Health (AWH) | 0.0 | $20k | 60k | 0.33 | ||
Sientra (SIEN) | 0.0 | $8.0k | 40k | 0.20 |
Past Filings by Birchview Capital
SEC 13F filings are viewable for Birchview Capital going back to 2014
- Birchview Capital 2022 Q4 filed Feb. 3, 2023
- Birchview Capital 2022 Q3 restated filed Nov. 28, 2022
- Birchview Capital 2022 Q3 filed Nov. 7, 2022
- Birchview Capital 2022 Q2 filed Aug. 12, 2022
- Birchview Capital 2022 Q1 filed May 13, 2022
- Birchview Capital 2021 Q4 filed Feb. 14, 2022
- Birchview Capital 2021 Q3 filed Nov. 12, 2021
- Birchview Capital 2021 Q2 filed Aug. 10, 2021
- Birchview Capital 2021 Q1 filed May 14, 2021
- Birchview Capital 2020 Q4 filed Feb. 9, 2021
- Birchview Capital 2020 Q3 restated filed Nov. 12, 2020
- Birchview Capital 2020 Q3 filed Nov. 12, 2020
- Birchview Capital 2020 Q2 restated filed Sept. 25, 2020
- Birchview Capital 2020 Q2 filed Aug. 10, 2020
- Birchview Capital 2020 Q1 filed May 12, 2020
- Birchview Capital 2019 Q4 filed Feb. 12, 2020